152 related articles for article (PubMed ID: 16183933)
1. Effect of dutasteride therapy on Doppler US evaluation of prostate: preliminary results.
Ives EP; Gomella LG; Halpern EJ
Radiology; 2005 Oct; 237(1):197-201. PubMed ID: 16183933
[TBL] [Abstract][Full Text] [Related]
2. Prostate: high-frequency Doppler US imaging for cancer detection.
Halpern EJ; Frauscher F; Strup SE; Nazarian LN; O'Kane P; Gomella LG
Radiology; 2002 Oct; 225(1):71-7. PubMed ID: 12354987
[TBL] [Abstract][Full Text] [Related]
3. Targeted biopsy of the prostate: the impact of color Doppler imaging and elastography on prostate cancer detection and Gleason score.
Nelson ED; Slotoroff CB; Gomella LG; Halpern EJ
Urology; 2007 Dec; 70(6):1136-40. PubMed ID: 18158034
[TBL] [Abstract][Full Text] [Related]
4. High-frequency Doppler US of the prostate: effect of patient position.
Halpern EJ; Frauscher F; Forsberg F; Strup SE; Nazarian LN; O'Kane P; Gomella LG
Radiology; 2002 Mar; 222(3):634-9. PubMed ID: 11867778
[TBL] [Abstract][Full Text] [Related]
5. Dutasteride prior to contrast-enhanced colour Doppler ultrasound prostate biopsy increases prostate cancer detection.
Mitterberger M; Pinggera G; Horninger W; Strasser H; Halpern E; Pallwein L; Gradl J; Bartsch G; Frauscher F
Eur Urol; 2008 Jan; 53(1):112-7. PubMed ID: 17321668
[TBL] [Abstract][Full Text] [Related]
6. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
Marks LS; Roehrborn CG; Wolford E; Wilson TH
J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742
[TBL] [Abstract][Full Text] [Related]
7. Effect of dutasteride on the risk of prostate cancer.
Andriole GL; Bostwick DG; Brawley OW; Gomella LG; Marberger M; Montorsi F; Pettaway CA; Tammela TL; Teloken C; Tindall DJ; Somerville MC; Wilson TH; Fowler IL; Rittmaster RS;
N Engl J Med; 2010 Apr; 362(13):1192-202. PubMed ID: 20357281
[TBL] [Abstract][Full Text] [Related]
8. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.
Roehrborn CG; Marks LS; Fenter T; Freedman S; Tuttle J; Gittleman M; Morrill B; Wolford ET
Urology; 2004 Apr; 63(4):709-15. PubMed ID: 15072886
[TBL] [Abstract][Full Text] [Related]
10. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
[TBL] [Abstract][Full Text] [Related]
11. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
[TBL] [Abstract][Full Text] [Related]
12. Optimal combinations for detection of prostate cancer: systematic sextant and laterally directed biopsies versus systematic sextant and color Doppler-targeted biopsies.
Kravchick S; Cytron S; Peled R; London D; Sibi Y; Ben-Dor D
Urology; 2004 Feb; 63(2):301-5. PubMed ID: 14972476
[TBL] [Abstract][Full Text] [Related]
13. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
Andriole GL; Marberger M; Roehrborn CG
J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
[TBL] [Abstract][Full Text] [Related]
14. Effect of short-term dutasteride therapy on prostate vascularity in patients with benign prostatic hyperplasia: a pilot study.
Kravchick S; Cytron S; Mamonov A; Peled R; Linov L
Urology; 2009 Jun; 73(6):1274-8. PubMed ID: 19375786
[TBL] [Abstract][Full Text] [Related]
15. Using gray-scale and color and power Doppler sonography to detect prostatic cancer.
Halpern EJ; Strup SE
AJR Am J Roentgenol; 2000 Mar; 174(3):623-7. PubMed ID: 10701599
[TBL] [Abstract][Full Text] [Related]
16. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.
Fleshner N; Gomella LG; Cookson MS; Finelli A; Evans A; Taneja SS; Lucia MS; Wolford E; Somerville MC; Rittmaster R;
Contemp Clin Trials; 2007 Nov; 28(6):763-9. PubMed ID: 17573244
[TBL] [Abstract][Full Text] [Related]
17. Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride.
Muller RL; Gerber L; Moreira DM; Andriole G; Hamilton RJ; Fleshner N; Parsons JK; Freedland SJ
Eur Urol; 2013 Jun; 63(6):1115-21. PubMed ID: 23541458
[TBL] [Abstract][Full Text] [Related]
18. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
Iczkowski KA; Qiu J; Qian J; Somerville MC; Rittmaster RS; Andriole GL; Bostwick DG
Urology; 2005 Jan; 65(1):76-82. PubMed ID: 15667867
[TBL] [Abstract][Full Text] [Related]
19. Comparison of contrast enhanced color Doppler targeted biopsy to conventional systematic biopsy: impact on Gleason score.
Mitterberger M; Pinggera GM; Horninger W; Bartsch G; Strasser H; Schäfer G; Brunner A; Halpern EJ; Gradl J; Pallwein L; Frauscher F
J Urol; 2007 Aug; 178(2):464-8; discussion 468. PubMed ID: 17561137
[TBL] [Abstract][Full Text] [Related]
20. Power doppler ultrasonography guided and random prostate biopsy in prostate cancer diagnosis - a comparative study.
Sohail SK; Sarfraz R; Imran M; Khan NA; Yusuf NW
J Pak Med Assoc; 2015 Jan; 65(1):65-8. PubMed ID: 25831678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
